NCT/Study#
NCT06116786 /
86974680NSC1001
A phase 1 study of JNJ-86974680, an A2a receptor antagonist, administered as monotherapy and in combination with cetrelimab and radiotherapy for advanced nonsmall cell lung cancer
DISEASE GROUP:
NSCLC
current phase:
Phase I
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
